Press releaseGlobe Newswire
Protara Therapeutics
TARA · NASDAQ
$2.56+$0.23 (+9.87%)TodayMarket closed ·
Prev close $2.33
Latest news
- Press releaseGlobe Newswire
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
- News
Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026
- Press releaseGlobe Newswire
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
- NewsVandana Singh
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer Study
- Press releaseGlobe Newswire
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
- Press releaseGlobe Newswire
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
- Press releaseGlobe Newswire
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsAvi Kapoor
Ultra Clean Posts Downbeat Earnings, Joins Paymentus, Whirlpool And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Press releaseGlobe Newswire
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
- News
Protara Therapeutics Enters 2026 With Advancing TARA-002 Programs, Registrational Trials And Extended Cash Runway Into 2028
- Press releaseGlobe Newswire
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- NewsAvi Kapoor
Why Ulta Beauty Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
What's Going On With Protara Therapeutics Stock Wednesday?
- Press releaseBusiness Wire
Catalio Capital Management Raises Over $400M to Invest in Innovative Healthcare Companies in its Fourth Venture Fund
- Press releaseGlobe Newswire
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- NewsAvi Kapoor
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook
- NewsAvi Kapoor
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings
- NewsAvi Kapoor
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
- Press releaseGlobe Newswire
Protara Highlights Recent Updates and Anticipated 2025 Milestones
- NewsChris Katje
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
- NewsAvi Kapoor
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Crude Oil Edges Lower; US Initial Jobless Claims Increase
- NewsAvi Kapoor
Dow Falls 50 Points; Kroger Posts Downbeat Sales
- Press releaseGlobe Newswire
Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.